Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine.

导出 OA

翻译打印收藏纠错

作者： Ujunwa Cynthia,Okoye-Okafor ^[1] ; Komal K,Javarappa ^[2] ; Dimitrios,Tsallos ^[3] ; Joseph,Saad ^[3] ; Daozheng,Yang ^[3] ; Chi,Zhang ^[1] ; Lumie,Benard ^[1] ; Victor J,Thiruthuvanathan ^[1] ; Sally,Cole ^[2] ; Stephen,Ruiz ^[1] ; Madhuri,Tatiparthy ^[2] ; Gaurav,Choudhary ^[1] ; Stefanie,DeFronzo ^[2] ; Boris A,Bartholdy ^[1] ; Celine,Pallaud ^[2] ; Pedro Marques,Ramos ^[1] ; Aditi,Shastri ^[2] ; Amit,Verma ^[4] ; Caroline A,Heckman ^[1] ; Britta,Will ^[1]

作者单位： Albert Einstein College of Medicine/Montefiore Medical Center, Department of Cell Biology, Bronx, NY. ^[1] Albert Einstein College of Medicine/Montefiore Medical Center, Cancer Stem Cell Pharmacodynamics Unit, Bronx, NY. ^[2] Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland. ^[3] Albert Einstein College of Medicine/Montefiore Medical Center, Department of Medicine (Oncology), Bronx, NY. ^[4] Novartis Pharmaceuticals, Basel, Switzerland. ^[5]

主题词阿扎胞苷(Azacitidine);人类(Humans);免疫, 先天(Immunity, Innate);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);骨髓增生异常综合征(Myelodysplastic Syndromes);血小板减少(Thrombocytopenia)

DOI 10.1084/jem.20212228

PMID 36053753

发布时间 2024-04-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交